American Journal of Infection Control

Pseudomonas aeruginosa (PA) is the third leading aetiological agent in healthcare-associated infections (HAIs); it is responsible for 10.23% of all HAIs in Spanish hospitals and is the most frequently found pathogen in mechanical ventilator

My timing could not have been better to reach out to the Association for Professionals in Infection Control and Epidemiology (APIC) requesting an Applied Practice Experience placement. As a research doctoral candidate focused on health equity in

Healthcare workers’ (HCWs) adherence to hand hygiene guidelines is vital in combatting infectious diseases, especially hospital-acquired infections and COVID-19 in hospitals1, 2. HCWs are front-line personnel and therefore frequently exposed to

Over 3 million patients annually receive home and specialty infusion services, typically through maintaining central venous catheters (CVCs) in the home for indications such as chemotherapy, home parenteral nutrition (HPN), and outpatient parenteral

The importance of hand hygiene in preventing healthcare-associated infections (HAI) is well established, with practice guided by the World Health Organization (WHO) “5 Moments for Hand Hygiene” framework1-3. This framework provides direction as to

Staphylococcus aureus causes over 30% of surgical site infections (SSIs)1 and these infections increase morbidity and healthcare costs.2-4 According to data from the National Health Safety Network 5 and data from individual medical centers, S. aureus

Contaminated environmental surfaces in healthcare facilities can contribute to transmission of healthcare-associated pathogens by serving as a source from which healthcare workers and patients can contaminate their hands.1,2 As a result, regular

Multiple studies have occurred to determine if a patient's blood type, Rhesus factor (Rh), and sociodemographic attributes contribute to contracting SARS-CoV-2. True association remains unknown.

The average healthcare-associated central line-associated bloodstream infection (CLABSI) costs $48,108.1 A CLABSI increases patient mortality by 12 to 25%.2 Additionally, with the COVID-19 pandemic beginning in 2020, there was shown to be a